CorporatePresentation

May 2020

ForwardLookingStatement

Thisdocumentandanyattachmentsareintendedforinformationpurposesonlyandshouldnotbeconstruedasonofferorsolicitationforthesaleofsecurities.Statements inthispresentationincludeforward-lookingstatementswithinthemeaningofcertainsecuritieslaws.Theseforward-lookingstatementsinclude,amongothers,statementswithrespecttoourobjectives,goalsandstrategiestoachievethoseobjectivesandgoals,aswellasstatementswithrespecttoourbeliefs,plans,objectives,expectations,anticipations,estimatesandintentions.Thewords “expected to” “illustrate” “has thepotential to” “willbe”, “evaluating” “plans” “canbe” “planning” “to predict” “potential” “may” “should” andwords and expressions of similar import, areintendedtoidentifyforward-lookingstatements.Resultsinearlystageclinicaltrialsmaynotbeindicativeoffullresultsorresultsfromlaterstageorlargerscaleclinicaltrialsanddonotensureregulatoryapproval.Youshouldnotputunduerelianceonthesestatementorthescientificdatapresentedasanumberofimportantfactors,manyofwhicharebeyondourcontrol,couldcauseouractualresultstodiffermaterially fromthebeliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements.We do not undertake to update any forward-looking statements,whetherwritten ororal,thatmaybemadefromtimetotimebyusoronourbehalf;suchstatementsspeakonlyasofthedatemade. The forward-looking statements included herein are expressly qualified in their entirety by thiscautionarylanguage.

MissionStatement

TeloGenomicsprovidesactionableinformationthatisrelevanttomedicalprofessionals in themanagementof cancer and cognitivedisease. It is adiagnostic company that applies innovative and minimally-invasiveanalysisofgenomicinstability,basedonthe3Dorganizationoftelomeres,toimprovequalityoflifeandreducetreatmentcost.

ExecutiveSummary

4

Genomicinstabilityiscriticalintheevolutionofprecisionmedicineforcancerandcognitivedisease

TeloView®uses3Danalyticsoftelomerestoanalyzegenomicinstabilityasadiseasepredictor

Focusingontherapidlyemergingfieldofminimallyinvasive/liquidbiopsy

Evaluatedover3,000patients,130+peer-reviewedpapers&$25millionnon-dilutivefunding

Opportunitiesindiagnostic/prognosticproducts,pharma&academicpartnerships

CollaborationwiththeMayoClinicfocusingonunmetclinicalneedsinmultiplemyeloma

TeloView®–ExtensivelyDevelopedPlatform

5

20+ diseaseswithidentifiable3D

telomeresignatures

3,000+ patientsevaluated

25+ confirmatoryclinical

studies

130+ peer-reviewedpapers

18 patentsinCanada,USA

&Europe

$25M+ innon-dilutiveR&D

funding

StrategicCollaboration–MayoClinic

6

Validation of TeloView® for two significant unmet prognostic needs in multiple myeloma (MM)

Study#1–ConfirmTeloView®canpredictpatientresponsetoinitialtherapyo  Choosingeffectivetherapyimprovespatient’schancesofgoingintoremissionanddelaystheonsetofpainfulsymptoms

Study#2–ConfirmTeloView®canpredictthetransitionofSmolderingMM(aprecursortoMM)toactiveMM

o  Identifyinghighriskpatientscanleadtoearliertreatment-delayingtheonsetofMM&itspainfulsymptoms

o  Identifyinglowriskpatientscaneliminatecostlytreatmentandimprovequalityoflife

Theaddressablemarketforthetwounmetneedsisover$1.0billion

Technology–TeloView®(3DTelomereAnalysis)

7

DNAispackagedintochromosomes.AtthetipsofeachchromosomeareprotectiveregionsofDNAcalledtelomeres

The3Dorganizationoftelomereswithinagivencellishighlypredictiveofgenomicinstability

AMeasureofGenomicInstability

Usingfluorescentmarkersandhighresolutionmicroscopes,thelocationofeachtelomerewithinacellnucleuscanbevisualizedanddigitallyanalyzed

TeloView®&GenomicInstability

8

TeloView®Single-cellAnalysis

-  Basedontheassessmentof6uniquetelomereparameters-  Cellsareanalyzedindividuallyusing3D-TelomereFISH*:

o  Representstheoverallgenomicinstabilityprofileofthepatiento  Canstratifypatientsbyprogression&theheterogeneityofcancers

-  Predictsresponsetotherapy&guidesprecisionmedicinetreatmentsolutions-  Requiresnomorethan100cellsanddoesnotrequireDNAamplification

First-in-class diagnostic/prognostic tool used to analyze genomic instability

Heterogeneityofcancer

-  Tumorsmayhavegroupsofcellsthatcontributedifferentlytotheaggressivenessofcancers-  Preciseprofilingofatumorshouldaccountforitsdistinctgroupsofcancercellsandrarecellsinguidingtreatment

*FISH FluorescentInSitu

Hybridization

Labelingoftelomereswithfluorescenttagscanbevisualizedandimagedin3Dusingamicroscope.Thefluorescentsignalscanthenbequantifiedtomeasurekeyfeaturesoftelomeres

TeloView®–WorkflowOutline

9

Personalized TeloView® Lab Report

TeloView®Analysis

ImageProcessing

3D Image Acquisition

3D – Telomere immuno-FISH

Sample Accession

4 5 6 1 3 2

Samples(fromblood,urine,etc.)areinspectedandassignedanID

Specificlabelingoftelomeresanddiseasespecificproteinswithfluorescenttags

Selectionofindividualtargetcells;AdaptimageformatforTeloView®analysis

1.#ofTelomeres2.Telomerelengths3.Telomereaggregates4.a:cRatio5.Nuclearvolume6.Positioninnucleus

Personalizedresultsthatinformandguidetreatment

Acquiresconsecutiveimagesatconsecutivefocalplanesacrossthedepthofthesampletobuildone3Dimage

PrecisionMedicine

-  Thetailoringoftherapiesforgroupsofstratifiedpatientsbasedongenomic,life-style&environmentalfactors

-  Itleadstoimprovedclinicaloutcomes&qualityoflifeforpatientsandreducescostsinthelong-term

- 

GenomicInstability

-  Adefiningfeatureandcauseofcancer&otherdiseases-  Isanincreasedtendencyofgenomicmutationsduringcelldivision

Adetailedanalysisofgenomicinstabilitycanbeusedtostratifypatientsbyprogressionoftheirdisease&guidetreatment*

Industry–PrecisionMedicine&GenomicInstability

10

*MaiS.Thethree-dimensionalcancernucleus.GenesChromosomesCancer.2019;58:462–473.https://doi.org/10.1002/gcc.22720

MinimallyInvasive/LiquidBiopsyvTissueBiopsy*

11

MinimallyInvasive/LiquidBiopsyo  Doesnotrequiresurgeryo  Usesliquids,hair,skin,etc.o  Capturescirculatingtumorcells(CTC’s)o  Faster,cheaper&painlesscomparedtosurgeryo  Repeatableformonitoringo  Providesgenomicanalysisofthenatureofcancers

Tissuebiopsyo  Requiresinvasivesurgeryo  Expensive($15000–$45,000)o  Painful&hardtorepeato  Riskofcomplicationso  Sideeffectso  Providesusefulgenomicinformation

*Marrugo-RamírezJ,MirMandSamitierJ.Blood-BasedCancerBiomarkersinLiquidBiopsy:APromisingNon-InvasiveAlternativetoTissueBiopsy.Int.J.Mol.Sci.2018,19,2877

LiquidBiopsyIndustry

12

•  Liquid-biopsyplatformsareattractingintenseinvestorinterest*•  Pharmacompanies&VC’sinvestedover$1.2Bnin2018**

NextGenerationSequencing(NGS)o  Prevalentinliquidbiopsyo  Allowshighspeedandlowcostgenomicsequencingo  RequiresisolationofDNAcellsfollowedbyamplification(theproductionofmultiplecopies

oftargetedsequencesofDNA)o  Requireslargerstudiestocompensateforchallengingsignal-to-noiseratioo  Risksmissingthepotentialheterogeneityofthecancer

*SheridanC.InvestorskeepthefaithincancerliquidbiopsiesNATUREBIOTECHNOLOGY|VOL37|SEPTEMBER2019|969–977**https://www.prnewswire.com/news-releases/liquid-biopsy-poised-to-revolutionize-prognosis-and-early-detection-300757046.html

•  TeloView®doesnotuseNGSorDNAamplification,earlystudieshaveshownTeloView®maybeequivalentorbetterinprofilingprostatecancerbyitsaggressiveness*

*DrachenbergD,AweJ,PozzoA,SaranchukJandMaiS.AdvancingRiskAssessmentofIntermediateRiskProstateCancerPatients.Cancers2019,11,855;doi:10.3390/cancers11060855

CompaniesofInterest

13

•  AdaptiveBiotechnologiesCorp.(Nasdaq:ADPTNGS)Raised$300million,IPOJune2019

•  GuardantHealth(Nasdaq:GHNGS)Raised$240million,IPOOctober2018

•  Grail,Inc.(PrivateNGS)Raised$1.5billionsince2016

•  Biocept,Inc.(Nasdaq:BIOCNGS)Raised$10million,December2019

•  LifeLength(PrivateTelomeres)Simple2Danalysis

TeloView®–MultipleMyeloma(MM)

14

•  Telo’sleadapplicationisadiagnostic/prognostictoolforunmetneedsacrossthespectrumofMM

•  MMisacancerofwhitebloodcells:o  Occursinplasmacells-atypeofwhitebloodcellthatgrowsinbonemarrowo  Symptomsincludebonepain/fractures,anemia,fatigue,recurrentinfections&kidney

problemso  Over140,000casesofMMintheUSin2020*o  Anincurablediseasethatcanbemoderatedthroughtreatment&hasa52%survival

rateover5years*

•  StandarddiagnosisforMMarebloodtestsandinvasivebonemarrowbiopsyandlimitedgenomictestingavailable

*https://seer.cancer.gov/statfacts/html/mulmy.html

MultipleMyeloma–DiseaseProgression

15

Initiation Progression

Clonalplasmacells

Post-germinalcentralBcell

MGUS SmolderingMultipleMyeloma

MultipleMyeloma

Plasmacellleukemia

Clonal,malignantplasmacells

•  Normalmatureplasmacells

•  Highlycomplicatedandaggressiveformofmyeloma

•  Symptomaticfullstageofthedisease

•  Abnormalmyelomacellsaccumulatedinthebonemarrow

•  AsymptomatichigherriskprecursorofMM

•  HigherlevelsofMproteins

•  Elevatedplasmainbonemarrow

•  AsymptomaticlowriskprecursorofMM

•  Mildlyelevatedantibodies(calledMproteins)

MultipleMyeloma–DiseaseProgression

16

TeloView®hasthepotentialtoguidediseasemanagementinmultipleareas

Initiation Progression

Post–germinalcentralBcell

MGUS

Clonalplasmacells

SmolderingMultipleMyeloma

MultipleMyeloma

Plasmacellleukemia

Clonal,malignantplasmacells

TELO-MM#2 TELO-MM#1

MayoCollaboration#1–MultipleMyeloma

17

MMistreatedwithcombinationtherapy,thereareover40differentcombinationsavailable,gettingtherightinitialtherapyiscritical:

o  Itcandelaysymptoms,bringonremissionandreducecostso  Patientsbuildupresistancetotherapyandcanchangecombinationsmultipletimeso  Typesoftreatmentincludes;chemotherapy,immunotherapy,proteasomeinhibitors,stemcell

therapyandradiationo  Annualcostoftherapyis$126-256ko  Thereareover32,000newcasesofMMayearintheUS*o  Addressablemarketforguidinginitialtherapyisover32,000testsperyear

AretrospectivestudydesignedtoshowsignificantdifferencesbetweenMMpatientswhofailedinitialtherapyfromthosewhoremainedinremission

InitialResponsetoTherapyinMM

*https://seer.cancer.gov/statfacts/html/mulmy.html

MayoCollaboration#2–MultipleMyeloma

18

AretrospectivestudydesignedtoshowsignificantdifferencesbetweenstableSMMpatientsvs.progressingSMMpatients

TransitionofSMMtoActiveMM

•  SMMisaprecursortoactiveMM:o  Standardofcarehasbeentomonitorbutnottreat,butischangingtoearlier

treatmentofhighriskpatientso  Currentdiagnosisisasimplebloodtestandinvasivebonemarrowbiopsyo  Thereareover250,000peoplewithSMMintheUS*o  13-14%SMMpatientstransitiontoactiveMMeachyear*

•  TeloView®isnon-invasive,itcanbeusedover2timesperyearinregularmonitoring•  Addressablemarketisover500,000testsperyear

TherearecurrentlynoteststhataccuratelypredictwhowilltransitionfromSMMtoactiveMM

*RavindranA,BartleyAC,HoltonSJ.Prevalence,incidenceandsurvivalofsmolderingmultiplemyelomaintheUnitedStates.BloodCancerJournal(2016)6,e486;publishedonline21October2016

MultipleMyeloma–RepresentativePublications

19

Summary#22016studyconductedon10patientsex-vivo

•  Tested3MMdrugsunderdevelopmentforefficacy•  SuccessfullyshowedthatTeloView®couldpredictpatientresponsetoeachdrug

-  Thefollowingkeysummariesarefrompeerreviewedpublications(2013-2019)-  Included158patientswithMM,SMMorMGUS&providedthecatalystfortheMayoCollaboration

Summary#12013studyincluded86patients

•  Establishedproofofconcept• Canbeconductedwithliquidbiopsy•  Stratifiespatientsbydistinct3Dtelomereprofilesforstageofthedisease

Summary#32019studyincluded62patients

• UsedTeloView®tostratifypatientsbydistinct3Dtelomereprofile•  Successfullystratified&groupedpatientsbetweenMGUS&activeMM

0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000

List

Pric

e ($

USD

) GenomicTesting=PremiumPricing

20

Commercialization

21

There are several potential paths to revenues: •  Licenseorsaledirectlytopharmaceuticalcompaniesforresearchorasa

companiondiagnostic•  Licenseorsalewithdiagnosticlaboratorycompaniesorestablisheddiagnostic

companies•  DirectsalesthroughasinglespecializedCLIAlaboratoryasaLabDevelopedTest

(LDT)•  Directsaleswithaninvitrodiagnostictest(IVT)underFDAapprovalasanew

product

TeloView®informsonarangeofcancersandneurologicaldiseases

22

Multiple MyelomaHodgkin’s LymphomaMyelodysplastic Syndrome/Acute Myeloid LeukemiaChronic Myeloid Leukemia

Prostate CancerAlzheimer’s Disease Lung Cancer (NSCLC)

Breast CancerMelanomaCutaneous LymphomaPancreatic CancerThyroid CancerHead and Neck CancerOral CancerEsophageal Cancer

TeloView®

Gastrointestinal CancerRhabdomyosarcomaEpendymomaCholangiocarcinomaGlioblastomaOligodendrogliomaNeuroblastoma

TELOLeadership

23

SabineMai,PhD,DirectorandChair,Clinical&ScientificAdvisoryBoardProfessor,UniversityofManitoba,TIER-ICanadaResearchChairfromTheCanadianInstituteofHealthResearch.Aworldleaderin3Dmicroscopy,telomeresbiology,genomicinstabilityandcancer.

SherifLouis,PhD,PMP,ChiefExecutiveOfficerAnexperiencedbusinessleaderandaccomplishedscientistwithstrongtrackrecordinthebiotechnologyindustryfocusedontechnologydevelopmentandcommercialization.

GuidoBaechler,Chairman25yearsofexperienceworkingwithemergingtechnologiesinlifesciences/medicaldiagnostics.ServedasPresident&ChiefExecutiveOfficerofSingulex.PriortoSingulex,heldexecutiveleadershippositionsatbothRocheDiagnosticsandRocheMolecularDiagnostics.

Clinical&ScientificAdvisoryBoard

24

Sabine Mai, PhD – Chair, Clinical & Scientific Advisory Board

Kenneth C. Anderson, MD – Harvard & Dana-Farber Cancer Institute (USA)

Laurence Klotz, MD – Sunnybrook Hospital (Canada) Hans Knecht, MD – McGill & The Jewish General Hospital (Canada)

Darrel Drachenberg, MD – CancerCare Manitoba (Canada)

Pubco&Capitalization

25

SharesIssued:

52-WeekRange:

RecentPrice:(01/05/20)

MarketCap:

PrivatePlacement:(11/25/2019)

ProjectBurnRate:

41.2m

$0.30-$0.10

$0.145

$6m

$1.74m

<$100k/mo.

InvestmentSummary

26

•  TeloView®isafirst-in-classprognostic/diagnostictoolusedtoanalyzegenomicinstabilityasapredictorofdiseaseandguidetreatment

•  Uniquespaceintherapidlyemergingfieldofminimallyinvasive/liquidbiopsy•  CollaborationwiththeMayoClinic,focusingonunmetclinicalneedsinmultiple

myeloma(MM),usingTeloView®topredict:o  EfficacyofinitialtherapyinMMo  TransitionfromsmolderingMMtoactiveMMo  Addressablemarketfortheseindicationsisover$1.0billion

•  Over130+peer-reviewedpapersevaluatingover3,000patientsand20+diseases•  Opportunitiesindiagnostic/prognosticproducts,pharmaceuticalpartnershipsand

academiccollaborations

ContactInformation

27

MaRSDiscoveryDistrict101CollegeSt.,Suite200Toronto,Ontario,Canada

E:info@telodx.comT:416.673.8487